02.18.14
A new study has indicated that adding TSI Group's proprietary processed PUREFLEX brand low molecular weight chondroitin sulfate to a glucosamine sulfate regimen provided a statistically significant reduction in loss of knee cartilage. The randomized, double blind and placebo-controlled Long-Term Evaluation of Glucosamine Sulfate (LEGS) study evaluated 605 subjects at the University of Sydney, Australia and was published last month by the BMJ Group.
The cartilage loss was measured as knee joint space narrowing (JSN). After two years of once-daily treatment with 1500 mg of glucosamine and 800 mg of TSI’s chondroitin, the reduction in JSN was approximately half of that demonstrated in the placebo group.
“These findings have exciting implications for knee joint sufferers,” said TSI Group's CEO Joe Zhou. “We're enthusiastic about the potential of PUREFLEX chondroitin as a tool in the fight against pervasive and difficult knee joint conditions.”
For more information: www.tsiinc.com
The cartilage loss was measured as knee joint space narrowing (JSN). After two years of once-daily treatment with 1500 mg of glucosamine and 800 mg of TSI’s chondroitin, the reduction in JSN was approximately half of that demonstrated in the placebo group.
“These findings have exciting implications for knee joint sufferers,” said TSI Group's CEO Joe Zhou. “We're enthusiastic about the potential of PUREFLEX chondroitin as a tool in the fight against pervasive and difficult knee joint conditions.”
For more information: www.tsiinc.com